Accurate expression of PD‐L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry. Issue 9 (31st July 2019)

• Record Type: Journal Article
• Authors: Shinchi, Yusuke; Komohara, Yoshihiro; Yonemitsu, Kimihiro; Sato, Kensaku; Ohnishi, Koji; Saito, Yoichi; Fujiwara, Yukio; Mori, Takeshi; Shiraishi, Kenji; Ikeda, Koei; Suzuki, Makoto
• Is Part Of: Cancer science. Volume 110:Issue 9(2019)
• Page Start: 2711
• Page End: 2721
• Publication Date: 2019-07-31
• Subjects: lung adenocarcinoma -- macrophage -- PD‐L1 -- PD‐L2 -- tumor proportion score; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.14128
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: The percentage of programmed death ligand 1 (PD‐L1) positivity in cancer cells, named as the tumor proportion score, is considered to be a predictive biomarker for anti‐PD‐1/PD‐L1 therapy in lung cancer. PD‐L1 is expressed on not only cancer cells but also on immune cells, including macrophages. Although previous studies related to PD‐L1/2 expression in cancer tissues have been generally based on single immunohistochemistry (IHC), in the present study, we attempted to evaluate accurate PD‐L1/2 expression in cancer cells in lung adenocarcinoma cells using double IHC to also evaluate macrophages. Of the 231 patients, PD‐L1 expression was negative in 169 patients (73.2%), 1%‐49% positive in 47 patients (20.3%), and ≥50% positive in 15 patients (6.5%). Interestingly, PD‐L1 positivity was decreased when using double IHC compared with the estimation by single IHC. High PD‐L1 expression was associated with high‐grade cancer cells and in higher stage cancer. PD‐L2 was negative in 109 patients (47.2%), 1%‐49% positive in 50 patients (21.6%), and ≥50% positive in 72 patients (31.2%). The number of PD‐L2‐positive patients was increased in cases that had an epidermal growth factor receptor ( EGFR ) mutation and in lower stage cancer. Thirty‐five patients (15.2%) were positive for both PD‐L1 and PD‐L2, whereas 81 patients (35.1%) were negative for both PD‐L1 and PD‐L2. Log‐rank analysis showed that progression‐free survival and overall survival were significantly the longest in the PD‐L1‐negative and PD‐L2‐positive groups ( P < .0001 and P = .0120). We observed lower PD‐L1 or PD‐L2 expression in lung adenocarcinoma than previously reported. Double IHC for macrophages may help clinicians to evaluate PD‐L1 or PD‐L2 expression specifically in cancer cells. Abstract : Double immunostaining of PD‐L1/2 and macrophages demonstrated the true tumor proportion score (TPS) of PD‐L1/2. True TPS was a prognostic factor for relapse‐free survival.